10:37 AM EDT, 06/03/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that a phase 3 trial of plozasiran in genetically confirmed or clinically diagnosed familial chylomicronemia syndrome, or FCS, met its primary endpoint of lowering triglycerides.

FCS is an ultrarare genetic disease that leads to extremely high triglyceride levels, the company said.

Data from the placebo-controlled study show that Plozasiran achieved statistically significant median reductions in triglycerides up to 80% at the 10-month mark, according to the company. The study also met all key secondary endpoints, including reduction in the incidence of pancreatitis, and the drug showed a favorable safety profile, the company added.

Arrowhead Chief Executive Christopher Anzalone said the company will communicate the results to the US Food and Drug Administration and discuss the filing of a new drug application for FCS.

Shares of Arrowhead Pharmaceuticals ( ARWR ) rose 8.6% in recent trading activity.

Price: 24.92, Change: +1.97, Percent Change: +8.58